Global Typhoid Vi Polysaccharide Vaccine Market Size By Type (Child, Adult), By Application (Government Institution, Private Sector), By Region, And Segment Forecasts, 2023 to 2032

lobal Typhoid Vi Polysaccharide Vaccine Market Report Description

The Global Typhoid Vi Polysaccharide Vaccine Market was valued at USD 350 million in 2023 and is projected to reach USD 612 million by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The market is primarily driven by the rising prevalence of typhoid fever in endemic regions, increased global awareness regarding immunization, and strategic public health initiatives. The Typhoid Vi polysaccharide vaccine, a subunit vaccine known for its efficacy in adults and children over two years, is increasingly being adopted in both routine immunization and outbreak response scenarios. Global initiatives, including those by Gavi, WHO, and UNICEF, are fueling demand across low- and middle-income countries.

Drivers:

1. Rising Prevalence of Typhoid Fever:

Typhoid remains a major health concern in South Asia, sub-Saharan Africa, and parts of Latin America. Increasing incidence rates are prompting governments and health organizations to prioritize preventive measures, particularly vaccination campaigns using Vi polysaccharide vaccines.

2. Supportive Public Health Policies and Immunization Programs:

Government-funded immunization campaigns and international health agency support, especially from Gavi and WHO, are significantly boosting the vaccine's reach in typhoid-endemic regions.

3. Cost-Effectiveness and Stability of Vi Polysaccharide Vaccines:

Compared to live attenuated or conjugate alternatives, Vi polysaccharide vaccines are less complex to manufacture, have favorable storage requirements, and are cost-effective for large-scale distribution.

Restraints:

1. Limited Efficacy in Children Under Two Years:

One of the key limitations is that Vi polysaccharide vaccines are not effective in infants below the age of two, necessitating reliance on conjugate vaccines in younger populations.

2. Competition from Conjugate Vaccines:

The growing preference for Vi conjugate vaccines due to their longer duration of immunity and effectiveness in younger children poses a competitive threat to the polysaccharide segment.

Opportunity:

1. Expansion in Travel and Military Health Programs:

Non-endemic regions are increasingly adopting Vi polysaccharide vaccines for travel and military personnel, providing new revenue streams outside the traditional public health sector.

2. Strategic Market Entry in Under-Vaccinated Regions:

Significant untapped potential exists in parts of Southeast Asia, Africa, and the Middle East, where access to typhoid vaccination remains low but disease burden is high.

Market by System Type Insights:

The Monovalent Vi Polysaccharide Vaccine segment held the largest market share in 2023. It is preferred due to its straightforward production, lower cost, and inclusion in several national immunization schedules. However, interest in combination vaccines is increasing, particularly in countries looking to reduce the number of injections in routine immunization programs.

Market by End-use Insights:

Public Health Agencies and Government Programs emerged as the dominant end-use segment in 2023, accounting for over 60% of global demand. Mass immunization efforts, especially in collaboration with international organizations, continue to drive procurement through public channels. Private clinics and travel medicine centers are gaining momentum in high-income countries and urban centers, contributing to market expansion.

Market by Regional Insights:

Asia-Pacific led the market in 2023, driven by high disease burden in countries such as India, Bangladesh, and Pakistan. The region benefits from strong government initiatives and partnerships with global health organizations. Africa represents the fastest-growing market, supported by increasing investment in vaccine distribution infrastructure. Meanwhile, North America and Europe see steady demand from travelers and military personnel.

Competitive Scenario:

Key players operating in the Global Typhoid Vi Polysaccharide Vaccine Market include Sanofi Pasteur, Bharat Biotech, Biological E. Limited, Bio-Med Pvt. Ltd., and Emergent BioSolutions. Companies are focusing on strategic distribution partnerships, product approvals in new markets, and expanding production capabilities to meet growing global demand.

Scope of Work – Global Typhoid Vi Polysaccharide Vaccine Market

Key Market Developments:

2023: Sanofi Pasteur expanded distribution of its Typhim Vi vaccine to African markets via new procurement deals with UNICEF.

2024: Bharat Biotech announced the scale-up of its polysaccharide vaccine production facility to meet rising international demand.

2025: WHO included Vi polysaccharide vaccine in updated immunization guidelines for adult outbreak response strategies in South Asia and Africa.

FAQs:

1) What is the current market size of the Global Typhoid Vi Polysaccharide Vaccine Market?

The market was valued at USD 350 million in 2023.

2) What is the major growth driver of the Global Typhoid Vi Polysaccharide Vaccine Market?

The primary growth driver is the rising incidence of typhoid fever and increased government-led immunization programs.

3) Which is the largest region during the forecast period in the Global Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific is expected to remain the largest region due to high disease burden and proactive vaccination policies.

4) Which segment accounted for the largest market share in Global Typhoid Vi Polysaccharide Vaccine Market?

The Monovalent Vi Polysaccharide Vaccine segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Typhoid Vi Polysaccharide Vaccine Market?

Key players include Sanofi Pasteur, Bharat Biotech, Biological E. Limited, Bio-Med Pvt. Ltd., and Emergent BioSolutions.

Let me know if you'd like this formatted into a downloadable document as well.